News

Merck & Co Inc (NYSE:MRK) has begun a Phase 3 clinical trial to test its experimental dengue vaccine in a pediatric ...
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...
Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...
Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...
Merck & Co. Inc. closed 39.23% short of its 52-week high of $134.63, which the company reached on June 25th.
Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...
Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...
Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...
The stock's fall snapped a three-day winning streak.
Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...